STOCK TITAN
  1. Home
  2. News
  3. MIRM

Mirum Pharmaceuticals Inc - MIRM STOCK NEWS

Welcome to our dedicated news page for Mirum Pharmaceuticals (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mirum Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mirum Pharmaceuticals's position in the market.

News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Mirum Pharmaceuticals (MIRM) granted inducement awards to nine new employees, including stock options and restricted stock units. The awards were approved by the Compensation Committee of Mirum's Board of Directors as inducements for employment. Each stock option has an exercise price of $25.63 per share and will vest over four years, while the RSUs will vest over three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
News
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Rhea-AI Summary
Mirum Pharmaceuticals receives positive HTA recommendation for reimbursement of LIVMARLI in Canada, marking a significant milestone in treating cholestatic pruritus in patients with Alagille syndrome. The recommendation by CADTH highlights the efficacy of LIVMARLI in reducing pruritus and bile acids, based on data from the ICONIC study. This approval expands access to the first approved therapy for this rare liver disorder in Canada, providing hope for patients and families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
-
News
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) receives FDA approval for LIVMARLI, an oral solution for cholestatic pruritus in PFIC patients. The approval is based on the Phase 3 MARCH study, showing significant reduction in pruritus severity. LIVMARLI also approved for Alagille syndrome. Immediate availability in the U.S. and plans for label expansion for younger patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
fda approval
News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. granted inducement awards to new employees, including stock options and restricted stock units. The awards are subject to vesting conditions over several years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
none
-
News
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) will participate in upcoming investor conferences, including Leerink Partners Global Biopharma Conference 2024 and Barclays Global Healthcare Conference 2024. The company aims to showcase its novel therapies for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
conferences
-
News
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) announces a significant 70% risk reduction in long-term clinical outcomes for patients with Alagille syndrome (ALGS) treated with LIVMARLI. The data show a six-year transplant-free survival benefit, marking a milestone in pharmacological intervention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
none
News
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) reported strong financial results for Q4 and year-end 2023 with net product sales of $178.9 million and full-year revenue of $186.4 million, showing 142% growth over 2022. Expecting global net product sales of $310-320 million in 2024. Key milestones include LIVMARLI PFIC PDUFA date on March 13, 2024, and interim analyses for Volixibat VISTAS and VANTAGE in first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
earnings
-
News
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) will report Q4 and year-end 2023 financial results on February 28, 2024, followed by a conference call to discuss financial results and corporate progress. Details for the call provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
earnings
-
News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. grants inducement awards to new employees involving stock options and restricted stock units. The awards are material to employment and align with Nasdaq rules, with options priced at $27.98 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. announces the approval of an inducement grant of non-qualified stock options and restricted stock units for their new Chief Medical Officer, Dr. Joanne Quan. The grant includes 75,000 shares of common stock and 37,500 RSUs under Mirum's 2020 Inducement Plan. The stock options have an exercise price of $26.72 per share and will vest over four years, while the RSUs will vest over three years. This grant was approved as an inducement material to Dr. Quan's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock MIRM logo
Mirum Pharmaceuticals Inc

Nasdaq:MIRM

MIRM Rankings

#2310 Ranked by Market Cap
#907 Ranked by Stock Gains
N/A Ranked by Dividends

MIRM Stock Data

1.16B
35.19M
2.25%
112.23%
17.36%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Foster City

About MIRM

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.